JP2019516789A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516789A5
JP2019516789A5 JP2019510578A JP2019510578A JP2019516789A5 JP 2019516789 A5 JP2019516789 A5 JP 2019516789A5 JP 2019510578 A JP2019510578 A JP 2019510578A JP 2019510578 A JP2019510578 A JP 2019510578A JP 2019516789 A5 JP2019516789 A5 JP 2019516789A5
Authority
JP
Japan
Prior art keywords
patent document
fulvestrant
international
publication
international publication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019510578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031376 external-priority patent/WO2017193048A1/en
Publication of JP2019516789A publication Critical patent/JP2019516789A/ja
Publication of JP2019516789A5 publication Critical patent/JP2019516789A5/ja
Priority to JP2021118471A priority Critical patent/JP7312523B2/ja
Priority to JP2023086732A priority patent/JP2023109959A/ja
Pending legal-status Critical Current

Links

JP2019510578A 2016-05-06 2017-05-05 フルベストラント配合物およびその使用方法 Pending JP2019516789A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021118471A JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662332842P 2016-05-06 2016-05-06
US62/332,842 2016-05-06
US201662420555P 2016-11-10 2016-11-10
US62/420,555 2016-11-10
PCT/US2017/031376 WO2017193048A1 (en) 2016-05-06 2017-05-05 Fulvestrant formulations and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021118471A Division JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2019516789A JP2019516789A (ja) 2019-06-20
JP2019516789A5 true JP2019516789A5 (enExample) 2020-04-30

Family

ID=58709642

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019510578A Pending JP2019516789A (ja) 2016-05-06 2017-05-05 フルベストラント配合物およびその使用方法
JP2021118471A Active JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A Pending JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021118471A Active JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A Pending JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Country Status (15)

Country Link
US (2) US20190134059A1 (enExample)
EP (1) EP3452011A1 (enExample)
JP (3) JP2019516789A (enExample)
KR (1) KR102438425B1 (enExample)
CN (1) CN109310621A (enExample)
AU (2) AU2017261321B2 (enExample)
CA (1) CA3022834A1 (enExample)
CO (1) CO2018013257A2 (enExample)
IL (2) IL285928B2 (enExample)
MA (1) MA44862A (enExample)
MX (2) MX2018013414A (enExample)
MY (1) MY205661A (enExample)
UA (1) UA125514C2 (enExample)
WO (1) WO2017193048A1 (enExample)
ZA (1) ZA201807031B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
MX2020004792A (es) 2017-11-08 2020-08-13 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos de su uso.
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法
CN114504551B (zh) * 2020-11-16 2024-01-02 北京厚燊维康科技有限责任公司 可用于光动力治疗或诊断的制剂
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US20030165568A1 (en) 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
GB0116619D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
PL367624A1 (en) * 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
JP2003298516A (ja) 2002-03-29 2003-10-17 Fujitsu Ltd 波長分散補償装置
EP1778187B1 (en) * 2004-08-04 2012-05-23 Camurus Ab Compositions forming non-lamellar dispersions
US8226926B2 (en) 2005-05-09 2012-07-24 Biosphere Medical, S.A. Compositions and methods using microspheres and non-ionic contrast agents
US20100166872A1 (en) 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101108168B (zh) * 2007-08-03 2010-12-08 西安力邦医药科技有限责任公司 一种氟维司群缓释微球的制备方法
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US9180088B2 (en) * 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
TW201016220A (en) * 2008-10-31 2010-05-01 Scinopharm Taiwan Ltd Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof
AU2010260226A1 (en) * 2009-06-18 2012-02-02 Abbvie Inc. Stable nanoparticulate drug suspension
JP5675803B2 (ja) * 2009-07-31 2015-02-25 シーアン リーバン メディカル テクノロジー シーオー., エルティーディーXi’An Libang Medical Technology Co., Ltd ミクロスフェア薬物担体、調製方法、組成物及びその使用
WO2011022861A1 (zh) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
WO2012021791A2 (en) 2010-08-13 2012-02-16 Scidose Llc Aqueous formulation with improved stability
NZ609420A (en) 2010-09-16 2015-06-26 Shimoda Biotech Pty Ltd Fulvestrant compositions and methods of use
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN103429267B (zh) 2011-01-09 2016-05-04 Anp科技公司 疏水分子诱导的支化聚合物集合体及其用途
BR112013029758A2 (pt) * 2011-05-20 2018-10-09 Capital, Business Y Gestion De Finanzas S.L. composição farmacêutica
CN102915088A (zh) 2011-08-03 2013-02-06 鸿富锦精密工业(深圳)有限公司 资料存储器固定装置
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CA2869377C (en) 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
KR101915942B1 (ko) * 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
JP2016536282A (ja) * 2013-10-03 2016-11-24 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. PI3Kα阻害剤を使用する強化された治療レジメン
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
US9757334B2 (en) 2014-07-02 2017-09-12 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
WO2015018380A2 (en) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof

Similar Documents

Publication Publication Date Title
JP2019516789A5 (enExample)
JP2019502892A5 (enExample)
JP2016153424A5 (enExample)
JP2014235432A5 (enExample)
JP2016135874A5 (enExample)
JP2014513484A5 (enExample)
CL2017003226A1 (es) Reguladores nrf2
JP2014138100A5 (enExample)
JP2015127343A5 (enExample)
JP2007327074A5 (enExample)
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
JP2018127649A5 (enExample)
JP2020528637A5 (enExample)
JP2017061637A5 (enExample)
CN109548403A (zh) Galunisertib的晶型及其制备方法和用途
CN109310676A (zh) 一种苯酚衍生物和依托咪酯的药物组合物、药物制剂及其用途
JP2016506003A5 (enExample)
JP2019527311A5 (enExample)
JP2014508098A5 (enExample)
JP2015042663A5 (enExample)
CN112584841A8 (zh) 肿瘤减小制剂及其使用方法
JP2013535391A5 (enExample)
JP2011082627A5 (enExample)
JP2021502362A5 (enExample)
ATE457731T1 (de) Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma